No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMLX Amylyx Pharmaceuticals
- 1.930
- +0.120+6.63%
Close May 1 16:00 ET
131.25MMarket Cap2.76P/E (TTM)
1.975High1.800Low1.80MVolume1.820Open1.810Pre Close3.47MTurnover3.50%Turnover Ratio2.76P/E (Static)68.01MShares30.50052wk High0.30P/B99.43MFloat Cap1.70052wk Low--Dividend TTM51.52MShs Float41.930Historical High--Div YieldTTM9.67%Amplitude1.700Historical Low1.923Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results
Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Amylyx Pharmaceuticals Price Target Cut to $3.00/Share From $4.00 by Baird
Amylyx Pharmaceuticals Price Target Cut to $3.00/Share From $4.00 by Baird
Baird Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
Baird analyst Joel Beatty maintains Amylyx Pharma with a Neutral and lowers the price target from $4 to $3.
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg